alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.
Company profile
Ticker
ALIM
Exchange
Website
CEO
Richard Eiswirth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Alimera Sciences Limited • Alimera Sciences Opthamologie GmbH • Alimera Sciences Europe Limited ...
ALIM stock data
Latest filings (excl ownership)
8-K
Alimera Appoints Maggie A. Pax to Its Board of Directors
8 Nov 23
10-Q
2023 Q3
Quarterly report
1 Nov 23
8-K
Alimera Sciences Reports Third Quarter 2023 Results
26 Oct 23
8-K
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
3 Oct 23
8-K
Unregistered Sales of Equity Securities
15 Aug 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Alimera Sciences Reports Second Quarter 2023 Results
10 Aug 23
8-K
Unregistered Sales of Equity Securities
2 Aug 23
424B3
Prospectus supplement
1 Aug 23
Transcripts
ALIM
Earnings call transcript
2023 Q3
26 Oct 23
ALIM
Earnings call transcript
2023 Q2
10 Aug 23
ALIM
Earnings call transcript
2023 Q1
18 May 23
ALIM
Earnings call transcript
2022 Q4
31 Mar 23
ALIM
Earnings call transcript
2022 Q3
14 Nov 22
ALIM
Earnings call transcript
2022 Q2
30 Jul 22
ALIM
Earnings call transcript
2022 Q1
9 May 22
ALIM
Earnings call transcript
2021 Q4
24 Feb 22
ALIM
Earnings call transcript
2021 Q3
28 Oct 21
ALIM
Earnings call transcript
2021 Q2
14 Aug 21
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm | 8.32 mm |
| Cash burn (monthly) | 3.50 mm | (no burn) | (no burn) | 1.41 mm | 3.28 mm | 1.52 mm |
| Cash used (since last report) | 8.11 mm | n/a | n/a | 3.27 mm | 7.60 mm | 3.53 mm |
| Cash remaining | 203.29 k | n/a | n/a | 5.05 mm | 717.53 k | 4.78 mm |
| Runway (months of cash) | 0.1 | n/a | n/a | 3.6 | 0.2 | 3.1 |
Institutional ownership, Q3 2023
| 13F holders | Current |
|---|---|
| Total holders | 31 |
| Opened positions | 12 |
| Closed positions | 0 |
| Increased positions | 5 |
| Reduced positions | 7 |
| 13F shares | Current |
|---|---|
| Total value | 146.23 bn |
| Total shares | 58.71 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Caligan Partners | 16.84 mm | $52.19 bn |
| Velan Capital Investment Management | 13.61 mm | $42.19 bn |
| Therapeutics OcuMension | 11.45 mm | $112.21 mm |
| Stonepine Capital Management | 3.98 mm | $12.35 bn |
| Boothbay Fund Management | 3.20 mm | $9.92 bn |
| Altium Capital Management | 2.93 mm | $9.10 bn |
| AIGH Capital Management | 2.37 mm | $7.35 bn |
| Clearline Capital | 2.34 mm | $7.24 bn |
| MS Morgan Stanley | 666.25 k | $2.07 bn |
| Worth Venture Partners | 593.71 k | $1.84 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Nov 23 | Philip Ashman | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.38 | 147,000 | 496.86 k | 147,000 |
| 21 Nov 23 | David Holland | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.38 | 100,000 | 338.00 k | 100,000 |
| 21 Nov 23 | Russell Skibsted | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.38 | 50,000 | 169.00 k | 50,000 |
| 7 Nov 23 | Margaret Pax | Stock Option Common Stock | Grant | Acquire A | No | No | 3.42 | 36,713 | 125.56 k | 36,713 |
News
Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented At The American Academy Of Ophthalmology
31 Oct 23
Earnings Scheduled For October 26, 2023
26 Oct 23
Alimera Sciences Q3 EPS $(0.06) Vs $(0.75) Last Year, Sales $23.36M Beat $22.72M Estimate
26 Oct 23
Alimera Announces Multiple Presentations Highlighting ILUVIEN And YUTIQ Data At Retina Society Annual Congress
11 Oct 23
On October 3, 2023, Alimera Sciences Appointed Jason Werner As The Company's Chief Operating Officer, Effective October 2: 8K
3 Oct 23
Press releases
Alimera Appoints Maggie A. Pax to Its Board of Directors
8 Nov 23
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
31 Oct 23
Alimera Sciences Reports Third Quarter 2023 Results
26 Oct 23
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
16 Oct 23
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
11 Oct 23